Study Finds Depo Provera Increases A Woman's Risk Of Getting
injectable contraceptives are more likely to acquire HIV than
In a recent study published in the journal Issues in
Law and Medicine researchers conducted a
meta-analysis to determine if existing research on the
use of DMPA increases a woman’s risk of getting HIV
transmitted by a male. The authors noted that studies
dating back to 1992 suggested that the use of DMPA put
women at a greater risk of contracting HIV.
Epidemiological and biological information was analyzed
to determine if enough evidence existed to qualify DMPA
as a danger to women’s health.
After analyzing research from 24 previous studies, the
authors found compelling evidence to characterize DMPA,
found in Depo-Provera and other injectable
contraceptives, a hazard to women’s health.
The findings from this meta-analysis
are consistent with the results of previous studies and
research. Noteworthy is that despite “substantial”
differences in the various studies’ designs, the authors
found it “striking” that all of the researchers came up
with “almost identical” results.
The authors concluded that “. . .DMPA has been shown to
weaken both the epithelial and immunological barriers to
HIV transmission.” Based on this evidence, the authors
stated that “DMPA adds significantly to the risk of male
to female HIV transmission.”
The authors strongly suggest that policy makers and
practitioners provide women with information on the
increased risk of contracting HIV while using DMPA.
Joel, Steven Condly, Steven W. Mosher, Anne Morse, Jennifer
Kimball.“Risk of HIV Infection in Depot-Medroxyprogesterone
Acetate (DMPA) Users: A Systematic Review and Meta-Analysis”
Issues in Law & Medicine
30, no. 2 (2015):129-139